Targeting CXCR1/CXCR2 receptor antagonism in malignant melanoma

Expert Opinion on Therapeutic Targets

Volumn 14, Issue 4, 2010, Pages 435-442

  Sharma, Bhawna ^a   Singh, Seema ^b   Varney, Michelle L ^a   Singh, Rakesh K ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF SOUTH ALABAMA   (United States)

Author keywords

Chemokine receptors; CXCR1; CXCR2; Melanoma; Targeted therapeutics

Indexed keywords

ANDROSTANOLONE; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR2; DACARBAZINE; ESTRADIOL; LIGAND; PROGESTERONE; SCH 479833; SCH 527123; UNCLASSIFIED DRUG;

ANGIOGENESIS; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER INHIBITION; CANCER STAGING; DRUG TARGETING; HUMAN; MELANOMA; METASTASIS; MODULATION; NONHUMAN; PATHOGENESIS; PHENOTYPE; PROTEIN EXPRESSION; REVIEW; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; HUMANS; LIGANDS; MELANOMA; NEOPLASM METASTASIS; RECEPTORS, INTERLEUKIN-8A; RECEPTORS, INTERLEUKIN-8B;

EID: 77949555355     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728221003652471     Document Type: Review

References (90)

1. Murphy PM, Baggiolini M, Charo IF, et al. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev 2000;52:145-176
2. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000;12:121-127
3. Balkwill F. Cancer and the chemokine network. Nat Rev Cancer 2004;4:540-550
4. Belperio JA, Keane MP, Burdick MD, et al. CXCR2/CXCR2 ligand biology during lung transplant ischemia-reperfusion injury. J Immunol 2005;175:6931-6939
5. Londhe VA, Belperio JA, Keane MP, et al. CXCR2/CXCR2 ligand biological axis impairs alveologenesis during dsRNA-induced lung inflammation in mice. Pediatr Res 2005;58:919-926
6. Strieter RM, Burdick MD, Gomperts BN, et al. CXC chemokines in angiogenesis. Cytokine Growth Factor Rev 2005;16:593-609
7. Mukaida N. Pathophysiological roles of interleukin-8/CXCL8 in pulmonary diseases. Am J Physiol Lung Cell Mol Physiol 2003;284:L566-77
8. Singh S, Sadanandam A, Singh RK. Chemokines in tumor angiogenesis and metastasis. Cancer Metastasis Rev 2007;26:453-467
9. Vandercappellen J, Van Damme J, Struyf S. The role of CXC chemokines and their receptors in cancer. Cancer Lett 2008;267:226-244
10. Richmond A, Yang J, Su Y. The good and the bad of chemokines/chemokine receptors in melanoma. Pigment Cell Melanoma Res 2009;22:175-186
11. Chapman RW, Phillips JE, Hipkin RW, et al. CXCR2 antagonists for the treatment of pulmonary disease. Pharmacol Ther 2009;121:55-68
12. Bertini R, Allegretti M, Bizzarri C, et al. Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury. Proc Natl Acad Sci USA 2004;101:11791-11796
13. Belperio JA, Keane MP, Arenberg DA, et al. CXC chemokines in angiogenesis. J Leukoc Biol 2000;68:1-8
14. Del Rio L, Bennouna S, Salinas J, Denkers EY. CXCR2 deficiency confers impaired neutrophil recruitment and increased susceptibility during Toxoplasma gondii infection. J Immunol 2001;167:6503-6509
15. Johnston RA, Mizgerd JP, Shore SA. CXCR2 is essential for maximal neutrophil recruitment and methacholine responsiveness after ozone exposure. Am J Physiol Lung Cell Mol Physiol 2005;288:L61-7
16. Hallgren J, Jones TG, Abonia JP, et al. Pulmonary CXCR2 regulates VCAM-1 and antigen-induced recruitment of mast cell progenitors. Proc Natl Acad Sci USA 2007;104:20478-20483
17. Stemmler S, Arinir U, Klein W, et al. Association of interleukin-8 receptor alpha polymorphisms with chronic obstructive pulmonary disease and asthma. Genes Immun 2005;6:225-230
18. Donahue TR, Hines OJ. CXCR2 and RET single nucleotide polymorphisms in pancreatic cancer. World J Surg 2009;33:710-715
19. Kamali-Sarvestani E, Aliparasti MR, Atefi S. Association of interleukin-8 (IL-8 or CXCL8) -251T/A and CXCR2 +1208C/T gene polymorphisms with breast cancer. Neoplasma 2007;54:484-489
20. Matheson MC, Ellis JA, Raven J, et al. Association of IL8, CXCR2 and TNF-alpha polymorphisms and airway disease. J Hum Genet 2006;51:196-203
21. Yang J, Zaja-Milatovic S, Thu YM, et al. Molecular determinants of melanoma malignancy: selecting targets for improved efficacy of chemotherapy. Mol Cancer Ther 2009;8:636-647
22. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-249
23. Varney ML, Johansson SL, Singh RK. Distinct expression of CXCL8 and its receptors CXCR1 and CXCR2 and their association with vessel density and aggressiveness in malignant melanoma. Am J Clin Pathol 2006;125:209-216
24. Singh RK, Varney ML, Bucana CD, Johansson SL. Expression of interleukin-8 in primary and metastatic malignant melanoma of the skin. Melanoma Res 1999;9:383-387
25. Singh S, Varney M, Singh RK. Host CXCR2-dependent regulation of melanoma growth, angiogenesis, and experimental lung metastasis. Cancer Res 2009;69:411-415
26. Singh S, Nannuru KC, Sadanandam A, et al. CXCR1 and CXCR2 enhances human melanoma tumourigenesis, growth and invasion. Br J Cancer 2009;100:1638-1646
27. Singh S, Sadanandam A, Nannuru KC, et al. Small-molecule antagonists for CXCR2 and CXCR1 inhibit human melanoma growth by decreasing tumor cell proliferation, survival, and angiogenesis. Clin Cancer Res 2009;15:2380-2386
28. Bar-Eli M. Role of interleukin-8 in tumor growth and metastasis of human melanoma. Pathobiology 1999;67:12-18
29. Ramjeesingh R, Leung R, Siu CH. Interleukin-8 secreted by endothelial cells induces chemotaxis of melanoma cells through the chemokine receptor CXCR1. FASEB J 2003;17(10):1292-1294
30. Wang JM, Taraboletti G, Matsushima K, et al. Induction of haptotactic migration of melanoma cells by neutrophil activating protein/interleukin-8. Biochem Biophys Res Commun 1990;169:165-170
31. Singh RK, Gutman M, Radinsky R, et al. Expression of interleukin 8 correlates with the metastatic potential of human melanoma cells in nude mice. Cancer Res 1994;54:3242-3247
32. Ugurel S, Rappl G, Tilgen W, Reinhold U. Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol 2001;19:577-583
33. Varney ML, Li A, Dave BJ, et al. Expression of CXCR1 and CXCR2 receptors in malignant melanoma with different metastatic potential and their role in interleukin-8 (CXCL8)-mediated modulation of metastatic phenotype. Clin Exp Metastasis 2003;20:723-731
34. Gebhardt C, Averbeck M, Viertel A, et al. Ultraviolet-B irradiation enhances melanoma cell motility via induction of autocrine interleukin 8 secretion. Exp Dermatol 2007;16:636-643
35. Singh RK, Gutman M, Reich R, Bar-Eli M. UV-B irradiation promotes tumorigenic and metastatic properties in primary cutaneous melanoma via induction of IL-8. Cancer Res 1995;55:3669-3674
36. Salcedo R, Resau JH, Halverson D, et al. Differential expression and responsiveness of chemokine receptors (CXCR1-3) by human microvascular endothelial cells and umbilical vein endothelial cells. FASEB J 2000;14:2055-2064
37. Li A, Varney ML, Valasek J, et al. Autocrine role of interleukin-8 in induction of endothelial cell proliferation, survival, migration and MMP-2 production and angiogenesis. Angiogenesis 2005;8:63-71
38. Addison CL, Daniel TO, Burdick MD, et al. The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR+ CXC chemokine-induced angiogenic activity. J Immunol 2000;165:5269-5277
39. Keane MP, Belperio JA, Xue YY, et al. Depletion of CXCR2 inhibits tumor growth and angiogenesis in a murine model of lung cancer. J Immunol 2004;172:2853-2860
40. Li A, Dubey S, Varney ML, et al. IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J Immunol 2003;170:3369-3376
41. Shono T, Ono M, Izumi H, et al. Involvement of the transcription factor NF-kB in tubular morphogenesis of human microvascular endothelial cells by oxidative stress. Mol Cell Biol 1996;16:4231-4239
42. Luca M, Huang S, Gershenwald JE, et al. Expression of interleukin-8 by human melanoma cells up-regulates MMP-2 activity and increases tumor growth and metastasis. Am J Pathol 1997;151:1105-1113
43. Xie K. Interleukin-8 and human cancer biology. Cytokine Growth Factor Rev 2001;12:375-391
44. Inoue K, Slaton JW, Eve BY, et al. Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. Clin Cancer Res 2000;6:2104-2119
45. McCawley LJ, Matrisian LM. Matrix metalloproteinases: multifunctional contributors to tumor progression. Mol Med Today 2000;6:149-156
46. Norgauer J, Metzner B, Schraufstatter I. Expression and growth-promoting function of the IL-8 receptor beta in human melanoma cells. J Immunol 1996;156:1132-1137
47. Singh RK, Gutman M, Reich R, Bar-Eli M. Ultraviolet B irradiation promotes tumorigenic and metastatic properties in primary cutaneous melanoma via induction of interleukin 8. Cancer Res 1995;55:3669-3674
48. Herlyn M. Human melanoma: development and progression. Cancer Metastasis Rev 1990;9:101-112
49. Ueda T, Shimada E, Urakawa T. Serum levels of cytokines in patients with colorectal cancer: possible involvement of interleukin-6 and interleukin-8 in hematogenous metastasis. J Gastroenterol 1994;29:423-429
50. Scheibenbogen C, Mohler T, Haefele J, et al. Serum interleukin-8 (IL-8) is elevated in patients with metastatic melanoma and correlates with tumour load. Melanoma Res 1995;5:179-181
51. Baggiolini M, Walz A, Kunkel SL. Neutrophil-activating peptide-1/ interleukin 8, a novel cytokine that activates neutrophils. J Clin Invest 1989;84:1045-1049
52. Norgauer J, Krutmann J, Dobos GJ, et al. Actin polymerization, calcium-transients, and phospholipid metabolism in human neutrophils after stimulation with interleukin-8 and N-formyl peptide. J Invest Dermatol 1994;102:310-314
53. Richardson RM, Ali H, Tomhave ED, et al. Cross-desensitization of chemoattractant receptors occurs at multiple levels. Evidence for a role for inhibition of phospholipase C activity. J Biol Chem 1995;270:27829-27833
54. Richardson RM, Dubose RA, Ali H, et al. Regulation of human interleukin-8 receptor A: identification of a phosphorylation site involved in modulating receptor functions. Biochemistry 1995;34:14193-14201
55. Richardson RM, Ali H, Pridgen BC, et al. Multiple signaling pathways of human interleukin-8 receptor A. Independent regulation by phosphorylation. J Biol Chem 1998;273:10690-10695
56. Feniger-Barish R, Ran M, Zaslaver A, Ben Baruch A. Differential modes of regulation of CXC chemokine-induced internalization and recycling of human CXCR1 and CXCR2. Cytokine 1999;11:996-1009
57. Mueller SG, White JR, Schraw WP, et al. Ligand-induced desensitization of the human CXC chemokine receptor-2 is modulated by multiple serine residues in the carboxyl-terminal domain of the receptor. J Biol Chem 1997;272:8207-8214
58. Wu D, Larosa GJ, Simon MI. G protein-coupled signal transduction pathways for interleukin-8. Science 1993;261:101-103
59. Richardson RM, Marjoram RJ, Barak LS, Snyderman R. Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J Immunol 2003;170:2904-2911
60. Jones SA, Moser B, Thelen M. A comparison of post-receptor signal transduction events in Jurkat cells transfected with either IL-8R1 or IL-8R2. Chemokine mediated activation of p42/p44 MAP-kinase (ERK-2). FEBS Lett 1995;364:211-214
61. Thelen M. Dancing to the tune of chemokines. Nat Immunol 2001;2:129-134
62. Jones SA, Dewald B, Clark-Lewis I, Baggiolini M. Chemokine antagonists that discriminate between interleukin-8 receptors. Selective blockers of CXCR2. J Biol Chem 1997;272:16166-16169
63. Chuntharapai A, Kim KJ. Regulation of the expression of IL-8 receptor A/B by IL-8: possible functions of each receptor. J Immunol 1995;155:2587-2594
64. Quan JM, Martin TR, Rosenberg GB, et al. Antibodies against the N-terminus of IL-8 receptor A inhibit neutrophil chemotaxis. Biochem Biophys Res Commun 1996;219:405-411
65. Dutt P, Wang JF, Groopman JE. Stromal cell-derived factor-1alpha and stem cell factor/kit ligand share signaling pathways in hemopoietic progenitors: a potential mechanism for cooperative induction of chemotaxis. J Immunol 1998;161:3652-3658
66. Ganju RK, Brubaker SA, Meyer J, et al. The alpha-chemokine, stromal cell-derived factor-1alpha, binds to the transmembrane G-protein-coupled CXCR-4 receptor and activates multiple signal transduction pathways. J Biol Chem 1998;273:23169-23175
67. Mellado M, Rodriguez-Frade JM, Aragay A, et al. The chemokine monocyte chemotactic protein 1 triggers Janus kinase 2 activation and tyrosine phosphorylation of the CCR2B receptor. J Immunol 1998;161:805-813
68. Takami M, Terry V, Petruzzelli L. Signaling pathways involved in IL-8-dependent activation of adhesion through Mac-1. J Immunol 2002;168:4559-4566
69. Gutkind JS. The pathways connecting G protein-coupled receptors to the nucleus through divergent mitogen-activated protein kinase cascades. J Biol Chem 1998;273:1839-1842
70. Gutkind JS. Cell growth control by G protein-coupled receptors: from signal transduction to signal integration. Oncogene 1998;17:1331-1342
71. Schraufstatter IU, Chung J, Burger M. IL-8 activates endothelial cell CXCR1 and CXCR2 through Rho and Rac signaling pathways. Am J Physiol Lung Cell Mol Physiol 2001;280:L1094-103
72. Wang D, Sai J, Carter G, et al. PAK1 kinase is required for CXCL1-induced chemotaxis. Biochemistry 2002;41:7100-7107
73. Jordan JD, Landau EM, Iyengar R. Signaling networks: the origins of cellular multitasking. Cell 2000;103:193-200
74. Schadendorf D, Moller A, Algermissen B, et al. IL-8 produced by human malignant melanoma cells in vitro is an essential autocrine growth factor. J Immunol 1993;151:2667-2675
75. Singh RK, Varney ML. Regulation of interleukin 8 expression in human malignant melanoma cells. Cancer Res 1998;58:1532-1537
76. Villares GJ, Zigler M, Wang H, et al. Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA. Cancer Res 2008;68:9078-9086
77. Melnikova VO, Bar-Eli M. Bioimmunotherapy for melanoma using fully human antibodies targeting MCAM/MUC18 and IL-8. Pigment Cell Res 2006;19:395-405
78. Fujisawa N, Hayashi S, Miller EJ. A synthetic peptide inhibitor for alpha-chemokines inhibits the tumour growth and pulmonary metastasis of human melanoma cells in nude mice. Melanoma Res 1999;9:105-114
79. Bendrik C, Dabrosin C. Estradiol increases IL-8 secretion of normal human breast tissue and breast cancer in vivo. J Immunol 2009;182:371-378
80. White JR, Lee JM, Young PR, et al. Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration. J Biol Chem 1998;273:10095-10098
81. Thatcher TH, McHugh NA, Egan RW, et al. Role of CXCR2 in cigarette smoke-induced lung inflammation. Am J Physiol Lung Cell Mol Physiol 2005;289:L322-8
82. Chapman RW, Minnicozzi M, Celly CS, et al. A novel, orally active CXCR1/2 receptor antagonist, Sch527123, inhibits neutrophil recruitment, mucus production, and goblet cell hyperplasia in animal models of pulmonary inflammation. J Pharmacol Exp Ther 2007;322:486-493
83. Becker JC, Kampgen E, Brocker E. Classical chemotherapy for metastatic melanoma. Clin Exp Dermatol 2000;25:503-508
84. Lev DC, Ruiz M, Mills L, et al. Dacarbazine causes transcriptional up-regulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: a possible escape mechanism from chemotherapy. Mol Cancer Ther 2003;2:753-763
85. Tawbi HA, Kirkwood JM. Management of metastatic melanoma. Semin Oncol 2007;34:532-545
86. De Larco JE, Wuertz BRK, Manivel JC, Furcht LT. Progression and enhancement of metastatic potential after exposure of tumor cells to chemotherapeutic agents. Cancer Res 2001;61:2857-2861
87. De Larco JE, Wuertz BRK, Rosner KA, et al. A potential role for interleukin-8 in the metastatic phenotype of breast carcinoma cells. Am J Pathol 2001;158:639-646
88. Acosta JC, Gil J. A role for CXCR2 in senescence, but what about in cancer? Cancer Res 2009;69:2167-2170
89. Maxwell PJ, Gallagher R, Seaton A, et al. HIF-1 and NF-kB-mediated upregulation of CXCR1 and CXCR2 expression promotes cell survival in hypoxic prostate cancer cells. Oncogene 2007;26:7333-7345
90. Uslu R, Sanli UA, Dikmen Y, et al. Predictive value of serum interleukin-8 levels in ovarian cancer patients treated with paclitaxel-containing regimens. Int J Gynecol Cancer 2005;15:240-245